Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-04-21

FDA Approved: ZYPREXA RELPREVV — Supplemental Application (H2-Pharma LLC)

View source ↗

Summary

FDA approved a supplemental application for ZYPREXA RELPREVV (olanzapine pamoate) from H2-Pharma LLC, authorizing changes to its regulatory approval for the lon…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ZYPREXA RELPREVV (olanzapine pamoate)

Snippet

SUPPL AP for ZYPREXA RELPREVV (OLANZAPINE PAMOATE)